Dr. Josep Vergés, CEO and President of OAFI International Foundation, has given two sessions at the Teófilo Hernández Institute (Autonomous University of Madrid) as a professor on the importance of the patient in clinical trials, within the Master in Monitoring and Coordination of Clinical Trials, which this year celebrates its 21st edition, directed by Professor Antonio García. Dr. Vergés gave the theoretical class “Osteoarthritis, a growing health and social problem” and a subsequent practical workshop on clinical trials.
Students who complete this master’s degree can enter the job market as a monitor or coordinator of clinical trials, or in departments of the pharmaceutical industry such as MSL, Medical Affairs, or Marketing Access among other options. The master’s degree is awarded by the Autonomous University of Madrid.
In December 2007, the Governing Board of the Autonomous University of Madrid approved the creation of the “Teófilo Hernando” Institute for R & D of Medicines. With this name we wanted to honor the figure of the first Spanish pharmacologist. The ITH currently has groups of researchers with experience in different phases of drug R + D + i, including molecular design and modelling, chemical synthesis, pharmacological screening, in vitro and in vivo models of disease and phase I to IV clinical trials. As a university institute equipped with laboratories and accredited phase I and II clinical trial units, we aspire to make the ITH a national and international reference in drug R + D + i. In fact, judging by the growing number of research projects contracted with public institutions and pharmaceutical companies, this reference is already a reality.
In June 2018, the Autonomous University of Madrid celebrated its 50th anniversary, during which time it has built up a recognised prestige through its quality teaching and research, becoming a leading public university.